Search International and National Patent Collections

1. (WO2018026203) COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS INCLUDING EXOSOME EXTRACTED FROM ADIPOSE-DERIVED STEM CELL AS ACTIVE COMPONENT

Pub. No.:    WO/2018/026203    International Application No.:    PCT/KR2017/008383
Publication Date: Fri Feb 09 00:59:59 CET 2018 International Filing Date: Fri Aug 04 01:59:59 CEST 2017
IPC: A61K 35/28
A61K 9/00
Applicants: EXOSTEMTECH CO., LTD.
주식회사 엑소스템텍
Inventors: CHO, Yong Woo
조용우
CHOI, Ji Suk
최지숙
YEOM, Seung Ho
염승호
JUNG, Youn Jae
정연제
Title: COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS INCLUDING EXOSOME EXTRACTED FROM ADIPOSE-DERIVED STEM CELL AS ACTIVE COMPONENT
Abstract:
The present invention relates to: a composition, which is for preventing or treating pulmonary fibrosis and includes an exosome extracted from an adipose-derived stem cell as an active component; a use of the exosome in the preparation of a pharmaceutical for preventing or treating pulmonary fibrosis; and a pulmonary fibrosis treatment method including a step for administering a subject with a pharmaceutical composition including the exosome as an active component. An exosome extracted from an adipose-derived stem cell according to the present invention includes growth factors, such as HGF (hepatocyte growth factor) and IL-10, related to pulmonary fibrosis treatment, and can significantly reduce the fibrotic region in pulmonary fibrosis-induced test animal models, and thus, can be usefully used in the prevention or treatment of pulmonary fibrosis. Moreover, in a pulmonary fibrosis treatment using an exosome according to the present invention, there is little concern of side effects from steroid-based drugs and antioxidants used in typical pulmonary fibrosis treatments occuring, and exosomes can be naturally transported to the lungs through injection- or ingestion-based administration, without surgical treatment, and thus, pulmonary fibrosis can be treated simply and economically.